PRKACA Mediates Resistance to HER2-Targeted Therapy in Breast Cancer Cells and Restores Anti-Apoptotic Signaling

Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive breast cancer leads to improved survival, but resistance is a common clinical problem. To uncover novel mechanisms of resistance to anti-HER2 therapy in breast cancer, we performed a kinase open reading frame (ORF) screen t...

Descripción completa

Detalles Bibliográficos
Autores principales: Moody, Susan E., Schinzel, Anna C., Singh, Shambhavi, Izzo, Francesca, Strickland, Matthew R., Luo, Leo, Thomas, Sapana R., Boehm, Jesse S., Kim, So Young, Wang, Zhigang C., Hahn, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261061/
https://www.ncbi.nlm.nih.gov/pubmed/24909179
http://dx.doi.org/10.1038/onc.2014.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261061/
https://www.ncbi.nlm.nih.gov/pubmed/24909179
http://dx.doi.org/10.1038/onc.2014.153

Ejemplares similares